Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Epizyme, Inc.

Eisai R&d Co., Ltd.

Wanjun Zheng

Boris M Seletsky

Yimin Jiang

Melvin J Yu

Mark Spyvee

Bruce A Littlefield

Fabian Gusovsky

Murray J Towle

Toshihiko Kaneko

Seiichi Kobayashi

Kenzo Muramoto

Hyeong-wook Choi

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Heather Davis

Jing Li

André Lescarbeau

Hong Du

Monica H Palme

Norihito Ohi

Jaemoon Lee

Xiang-Yi Li

Bruce Decosta

Hiromitsu Yokohama

Robert Yu

Daniel Custar

Marc Pesant

Ye Yao

Xiaojie Zhu

Yan (Janet) Zhao

Jane Daun

Maarten Postema

Lynda Tremblay

Kevin Wayne Kuntz

John Emmerson Campbell

Masashi Seki

Syuji Shirotori

Frank Fang

Wataru Itano

Francis Gerard Fang

Sally T Ishizaka

Monica Palme

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Substituted benzene compounds

We provide compounds given by Formula I, which is shown in FIG., or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

EP4 antagonists

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

The present invention provides benzoxazole compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions including the same. The present invention further provides methods of use as described herein.

Benzoxazole compounds and methods of use

The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer, and intermediates for the synthesis of such compositions.

Methods and compositions for use in treating cancer

The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Intermediates in the preparation of macrocyclic analogs

Intermediate compounds for preparing macrocylcic analogs

The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.

Macrocyclic analogs and methods of their use and preparation

Growing community of inventors

Londonderry, NH, United States of America

Wanjun Zheng